STS01 1% effectively promotes hair regrowth with minimal side effects.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
The FDA did not approve a testosterone drug because of safety concerns.
21 citations
,
February 2006 in “Clinical Cancer Research” Mitf plays a key role in melanoma progression and is linked to disease stage.
3 citations
,
July 2025 in “International Immunopharmacology” September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
1 citations
,
June 1999 in “American Journal of Contact Dermatitis” Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
October 2007 in “Inpharma Weekly”
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
7 citations
,
April 2013 in “Clinical and Experimental Dermatology” Tianeptine, an antidepressant, may prevent stress-induced hair loss in mice.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
7 citations
,
September 2021 in “Antimicrobial Agents and Chemotherapy” Olorofim effectively treats fungal skin infections.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
1 citations
,
May 2025 in “Current Issues in Molecular Biology” Centipeda minima and brevilin A protect skin cells from damage and aging.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
77 citations
,
January 1980 in “Carcinogenesis” TPA is about 50 times more effective at promoting tumors than MZ.
1 citations
,
January 2017 in “Journal of Clinical Trials & Patenting” The lotion safely and effectively reduces unwanted hair growth.
July 2024 in “Journal of Investigative Dermatology” Topical melatonin may reduce skin aging by inhibiting certain cellular pathways.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
5 citations
,
June 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Putting thymidine dinucleotide on newborn mice's skin can delay and reduce skin cancer.